Acute myeloid leukaemia
Not recruitingStudy Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics
Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics
- Disease:Acute myeloid leukaemia
- Substances:CytarabineDaunorubicin
Austria- Participants:18–64 years · 65+ years
- Substances:Cytarabine
- Sponsor:Universitaetsklinikum Ulm AöR













